Overview

To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

To demonstrate that CT-P16 is similar to US-approved Avastin in terms of efficacy determined by overall response rate (ORR) up to Cycle 6 during the Induction Study Period

Phase:

Phase 3

Details

Lead Sponsor:

Celltrion

Treatments:

Bevacizumab